On April 29, 2020 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported three clinical presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) upcoming ASCO (Free ASCO Whitepaper)20 Virtual Scientific Program to be held May 29-31, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ASCO Virtual Presentations

Title: A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms
Authors: Jason J. Luke, et al.
Session: Developmental Therapeutics—Immunotherapy
Session Type: Oral Abstract Session
Abstract: 3004

Title: Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors
Authors: John D. Powderly, et al.
Session: Developmental Therapeutics—Immunotherapy
Session Type: Poster Abstract Session
Abstract: 3071
Poster: 135

Title: SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC)
Authors: Santiago Escrivá, et al.
Session: Breast Cancer—Metastatic
Session Type: Poster Abstract Session
Abstract: 1040
Poster: 125

Presentations will be available for on-demand viewing online at View Source beginning on May 29, 2020 at 8:00 a.m. ET.